Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apnex secures $16.1m in series A:

This article was originally published in Clinica

Executive Summary

Minneapolis, Minnesota-based Apnex Medical, a subsidiary of Prospex Medical, will finance the initiation of clinical studies of its implantable technology for the treatment of obstructive sleep apnea with $16.1m of private funding. Domain Associates, New Enterprise Associates, Polaris Venture Partners and Michael Berman, current active chairman of Apnex and co-founder of Prospex, all participated in the series A financing. Obstructive sleep apnea is the most significant form of a condition that causes restricted breathing during sleep. Sleep apnea affects an estimated 18 million Americans, according to the American Lung Association.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts